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Abstract: Prostate cancer is the second most common malignancy affecting men worldwide, and the 
commonest affecting men of African descent. Significant diagnostic and therapeutic advances have been 
made in the past decade. Improvements in the accuracy of prostate cancer diagnosis include the uptake of 
multi-parametric MRI and a shift towards targeted biopsy. We also now have more life-prolonging systemic 
and hormonal therapies for men with advanced disease at our disposal than ever before. However, the 
development of robust screening tools and targeted screening programs has not followed at the same pace. 
Evidence to support population-based screening remains unclear, with the use of PSA as a screening test 
limiting our ability to discriminate between clinically significant and insignificant disease. Prostate cancer has 
a large heritable component. Given that most men without risk factors have a low lifetime risk of developing 
lethal prostate cancer, much work is being done to further our knowledge of how we can best screen 
men in higher risk categories, such as those with a family history (FH) of the disease or those of African 
ancestry. These men have been reported to carry upwards of a two-fold increased risk of developing the 
disease at an earlier age, with evidence suggesting poorer survival outcomes. In men with a FH of prostate 
cancer, this is felt to be due to rare, high-penetrance mutations and the presence of multiple, common low 
penetrance alleles, with men carrying specific germline mutations in the BRCA and other DNA repair 
genes at particularly high risk. To date, large scale genome-wide association studies (GWAS) have led to the 
discovery of approximately 170 single nucleotide polymorphisms (SNPs) associated with prostate cancer 
risk, allowing over 30% of prostate cancer risk to be explained. Genomic tests, utilising somatic (prostate 
biopsy) tissue can also predict the risk of unfavourable pathology, biochemical recurrence and the likelihood 
of metastatic disease using gene expression. Targeted screening studies are currently under way in men with 
DNA repair mutations, men with a FH and those of Afro-Caribbean ethnicity which will greater inform 
our understanding of disease incidence and behaviour in these men, treatment outcomes and developing the 
most appropriate screening regime for such men. Incorporating a patient’s genetic mutation status into risk 
algorithms allows us an opportunity to develop targeted screening programs for men in whom early cancer 
detection and treatment will positively influence survival, and in the process offer male family members of 
affected men the chance to be counselled and screened accordingly.
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Introduction 
Prostate cancer remains one of the most commonly diagnosed 
cancers in men in the western world, with 1.1 million 
new cases annually and 307,000 deaths (1). It is the 
commonest cancer in UK with Caucasian males having 
a lifetime risk of 13.2–15% of developing the disease (2). 
However, not all men are at equal risk for developing 
the lethal form of the disease, and the vast majority will 
have unaffected overall survival (3). Both the ProtecT 
and PIVOT studies of PSA screened men demonstrated 
no difference in disease-specific or all-cause mortality 
irrespective if men were treated or just observed (4,5). 
What we do know, is men with a family history (FH) of 
prostate cancer or those of Afro-Caribbean ancestry have a 
susceptibility to earlier onset and more aggressive disease 
making them an ideal group of men in whom to establish 
robust screening tools to improve survival by means of early 
diagnosis and treatment (6). 
Genetics of prostate cancer in men with a FH 
and black men 
Men with a FH of prostate cancer have a significantly 
higher lifetime risk of developing the disease, with a 2- to 
8-fold increase reported (7) and worsening risk with the 
number of first degree relatives affected. A Swedish study 
reporting from a family-database of over 9 million people 
reported a standardized incidence ratio (SIR) of 23.72 for 
men whose father and sibling were affected (8). Further 
work in the same cohort established an SIR of 8.05 of 
developing prostate cancer before age 55, if a brother was 
affected before this age (9). Another group screened 34 first-
degree relatives (sons/brothers) of 17 sets of (two) brothers 
with prostate cancer, using a combination of PSA, DRE and 
TRUS biopsy. Clinically significant, asymptomatic prostate 
cancer was found in 8 (24%) men with a reported RR of 
developing prostate cancer of 5–11 (10).
In a retrospective assessment of American men with a FH 
of prostate cancer undergoing prostate biopsies for either a 
raised PSA or abnormal DRE, it was found these men were 
significantly more likely to be diagnosed with both low-
grade and high-grade prostate cancer (11). 
Retrospective studies of prostate cancer incidence in the 
USA and Africa reveal a higher disease occurrence in black 
men compared with white men (12). Age at disease onset 
is earlier, with tumours reported to be more aggressive (2). 
Mortality rates also significantly differ between African 
and Caribbean men compared with the UK, as depicted in 
GLOBOCANs mortality and incidence data (Figure 1). 
The PROCESS study examined 2,140 cases of prostate 
cancer in defined areas of London and Bristol with high 
proportions of black male residents, with black men being 
three times more likely to develop prostate cancer than 
white men but with no significant difference between 
black-African and black-Caribbean men (13). The most 
recent USA [2014] incidence and death rates per 100,000 
population for black men with prostate cancer compared 
with white men, were 154.1 (86.9 in whites) and 38.0 (17.9 
in whites) respectively (14).
Population screening for prostate cancer
Screening for prostate cancer would clearly aim to detect 
clinically important cancers, in parallel to not exposing 
men to the morbidity of unnecessary prostate biopsies and 
diagnosing clinically insignificant prostate cancer. Few 
other specialities have been as plagued with controversy 
as prostate cancer diagnostics, since the advent of PSA as 
tumour marker after its isolation from the serum of 219 
patients with prostate cancer by Papsidero in 1981 (15). 
Work performed in the 1980s (16) produced evidence that 
although PSA is related to prostate cancer, its levels also 
rose in the presence of BPH rendering its relationship to 
prostate cancer diagnosis in Stamey’s own words as ‘tenuous 
at best’ (17).
In essence, PSA remains an imperfect screening tool in 
isolation for discriminating between a clinically significant 
cancer, and one which may have never affected a man 
during the course of his lifetime. The US Preventive 
Services Taskforce (USPSTF) report on this ‘pseudo-
disease’ situation in their 2012 recommendation, citing the 
benefits of PSA screening as ‘small and potentially none, 
and the harms are moderate to substantial’ (18).
The UK national screening committee (NSC) last 
recommended in January 2014 there was not enough 
evidence to commence a national screening program, 
given significant limitations in PSA’s ability to perform 
as a robust screening tool. The harms of overdiagnosis 
and overtreatment were felt to clearly still outweigh the 
potential 21% reduced risk on mortality (19). 
In a report to the NSC in March 2013, the University of 
Sheffield assessed the outcomes of four different screening 
options; a single screen at age 50, screening every 4 years 
age 50–74, screening every 2 years age 50–74 and screening 
annually aged 50–74. They estimated all repeat screening 
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policy options were associated with 45–65% risk of 
overdetection of prostate cancer, with a rate of 30–40% for 
a single screen policy and in order to obtain 1 additional 
year of life, repeat screening policies are associated within 
the region of 22–32 years of additional prostate cancer 
management. Finally, they estimated an overall expected 
survival benefit of 2–4 days per person invited for a single 
screen aged 50, and 20–60 days for the repeat screen 
policies (20).
Pashayan et al. assessed the implications of using 
polygenic risk scoring (PRS) on reducing overdiagnosis. 
They constructed a PRS on 17,000 men aged 50–69 from 
three large studies [ProtecT, SEARCH and the UK Genetic 
Prostate Cancer Study (UKGPCS)] using 66 known SNPs, 
separating men with and without prostate cancer into risk 
quartiles. By introducing this method, they found a 56% 
reduction in overdiagnosis between the lowest risk quartile 
and the highest (21). In a separate study the same author 
examined 43,842 men within the ProtecT study alone, aged 
50–69. A PSA threshold of ≥3.0 ng/mL−1 was used, with 3.5% 
of men being diagnosed with prostate cancer. It was estimated 
that 10–31% of these cases were overdiagnosed (22). 
Moving towards developing specific risk-based strategies 
and targeting certain groups of men would allow us to 
expose less ‘low risk’ men to the harms of false-positive PSA 
testing and increase the usefulness of a screening program. 
The Rotterdam prostate cancer risk calculator developed 
by Roobol et al. describes a screening algorithm applied to 
1,850 men within the Rotterdam section of the ERSPC. 
They calculated the probability of having a diagnosis of 
indolent prostate cancer detected on biopsy. Of the 1,850 
men, 541 were diagnosed with prostate cancer on biopsy 
with an estimate of 44% of these likely to be indolent. 
Applying their algorithm, using a PSA biopsy threshold 
ASR (W) per 100,000, all ages
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Figure 1 WHO Prostate cancer incidence and mortality figures by continent. Higher mortality noted in the Caribbean, Southern, Middle, 
Western and Eastern Africa, taken from Globocan (http://globocan.iarc.fr/Default.aspx) (1).
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of ≥3.0 ng/mL and taking into account previous screening 
visits significantly reduced the number of unnecessary 
biopsies (23). 
Evidence for targeted screening 
We know certain groups of men have an elevated risk of 
an early onset of disease and for developing lethal prostate 
cancer. Men with a FH of prostate cancer and black men 
have repeatedly been shown to be at higher risk but a full 
explanation of the exact genetic mechanism eludes us still. 
It seems sensible therefore to investigate the best way of 
adopting screening programs in these specific groups of 
men, who are well placed to theoretically truly benefit from 
early cancer detection and treatment. 
Interrogating the PLCO data, Liss et al. found that 
when they looked at all men within the study who had 
a FH of prostate cancer, those who were screened had a 
trend towards decreased prostate cancer specific mortality 
and time to death, with a significantly higher incidence 
of prostate cancer and mortality in all men with a FH 
compared to those without (6).
There is evidence to suggest genetic based scores 
improve prostate cancer detection and risk stratification. 
Using 14 known prostate cancer associated SNPs and the 
presence/absence of a FH of prostate cancer, Xu et al. built 
a risk prediction model. They concluded an OR of 4.92 for 
developing prostate cancer for men with a positive FH and 
≥14 risk alleles for the Swedish cohort in their study (24) . 
Using data from the REDUCE trial (Reduction by 
Dutasteride of Prostate Cancer Events) which assessed 
the chemopreventive benefits of Dutasteride, Kader and 
colleagues analysed germline DNA from 1,654 controls. 
These men all had an initial negative prostate biopsy, with 
subsequent prostate biopsies at 2 and 4 years. They found 
adding a genetic score based on 33 risk SNPs with clinical 
variables was an independent prostate cancer risk predictor 
on repeat prostate biopsy, and demonstrated ability to 
reduce the number of repeat biopsies required (25). 
High risk susceptibility protein-coding genes in 
prostate cancer
HOXB13
High-risk prostate cancer predisposition genes exist, with 
carriers of a rare missense mutation (G84E) of the HOXB13 
gene having a 33% risk of developing prostate cancer, 
compared to a 12% risk of non-carriers when studied in a 
Swedish population. This mutation was present in 1.3% of 
population controls and >4% of cases (26). Further large-
scale analysis of 4,000 prostate cancer cases in Finland for 
this specific mutation revealed a significantly higher carrier-
rate amongst men with prostate cancer (3.5%) and those 
with a FH (8.4%) compared to controls (27). In a separate 
study of 5,083 unrelated European subjects who had prostate 
cancer, Ewing et al. found the carrier rate of the (G84E) 
mutation was increased by a factor of approximately 20. 
This mutation was significantly more common in men with 
disease at a young age and with a positive FH (1.4%), than 
those without (0.1%) (28) . This genetic mutation therefore 
seems particularly significant in young men with prostate 
cancer and with a strong FH in Finnish and Swedish 
populations.
DNA repair genes
Germline deleterious mutations in BRCA1/2 genes increase 
the risk of developing prostate cancer. Edwards et al. (29) 
reported the prevalence of a BRCA2 mutation to be 2.3% in 
young men presenting with PSA detected prostate cancer. 
The authors’ further analysis of 21 young men with prostate 
cancer who had BRCA2 mutations compared to approx. 
1,500 controls demonstrated poorer overall survival (30) 
with an Icelandic study showing a mean survival of only 2.1 
years in men with prostate cancer with the specific 999del5 
BRCA2 mutation compared with non-carriers (31). Two 
further retrospective analyses found association between 
BRCA status and higher risk of disease recurrence, prostate 
cancer specific-mortality and high risk disease with a 
significant difference in CSS of 8.6 vs. 15.7 years for non-
carriers (32,33). 
Mutations of other genes involved in DNA repair such 
as ATM, CHEK2, MSH1, MLH1, MSH2, and MSH6 have 
also been associated with a high risk of developing prostate 
cancer, following analysis of a mainly white, European 
cohort of men in the UKGPCS study (34,35). In this study 
7.3% of cases of prostate cancer patients with a positive 
FH were found to carry a germline mutation. The most 
frequent mutation was in BRCA2 (28.57% of all mutations), 
and importantly there was a significant association between 
genetic mutation carrier status with nodal and metastatic 
disease. A further review by Pritchard et al. of 692 men 
with metastatic castrate resistant prostate cancer revealed a 
germline DNA repair-gene mutation in 11.8% of all men, 
across 16 genes including BRCA1/2, ATM, CHEK2, PALB2 
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and RAD51D (36). A genetic mutation (657del5) in NBN 
has also been associated with a significantly higher risk of 
earlier onset disease, aggressive histology and reduced 5- 
and 10-year survival in a Polish cohort of approximately 
3,800 men (34). 
Germline single nucleotide polymorphisms 
(SNPs) in prostate cancer
Aside from high-penetrance mutations as described above, 
more common alleles (SNPs) associated with prostate 
cancer can occur in up to 5% of the population. These low-
penetrance genetic variations can confer a low risk of prostate 
cancer risk if occurring alone, but result in an elevated and 
potentially clinically relevant risk when multiple SNPs occur 
together, strengthening their genetic effect. Large scale 
genome-wide association studies (GWAS), have led to the 
discovery of up to 170 SNPs associated with prostate cancer 
risk (37-40). Pending imminent publication of the latest 
susceptibility loci from the Oncoarray Initiative (41), 30% of 
the familial risk in prostate cancer can be explained based on 
previously published SNPs, with men in the top 1% of the 
risk profile having a 4.7-fold increase in risk of developing 
prostate cancer compared with controls (42).
Zheng & colleagues published their results examining 
the effect of the five commonest known SNPs associated 
with prostate cancer. They found their presence in 
combination with a FH accounted for 46% of the cases 
of prostate cancer in their cohort and conferred an odds 
ratio of 9.46 compared with men who had none of these 
factors, independent of PSA. Pending the results of current 
screening studies in high-risk men, it would appear that 
using genetic information with PSA and FH information 
could translate into a breakthrough in improving prostate 
cancer screening (40). 
Precision oncology and genomic tests available 
for prostate cancer
Precision oncology and targeted cancer therapy based on 
somatic and germline mutations are expected to soon form 
a significant part of cancer care. Robinson et al. recently 
published a series of 500 adult patients with metastatic solid 
tumours, revealing 12.2% of cases carrying a pathogenic 
germline mutation, of which 75% were in DNA repair 
genes. This emphasises the clinical relevance of obtaining 
genomic information to map patients’ individual tumour 
genotype and phenotype to offer targeted oncological 
therapies (43). 
Work from the Stand Up To Cancer (SU2C) Prostate 
Cancer Foundation Dream Team will discover and deliver 
precision therapy for advanced prostate cancer, targeting 
adaptive pathways in hormone-resistant disease and aiming 
to deliver individualised treatment to prostate cancer 
patients based on the genetic characteristics of their tumour 
(http://www.standuptocancer.org/dream_teams/view/
targeting_adaptive_pathways_in_metastatic_crpc). 
Mapping the mutational burden of both somatic tissue 
in prostate cancer and germline DNA in delivering specific 
therapeutic agents is already under way in the TOPARP and 
the BARCODE 2 studies (44,45). In 2015, Robinson et al. 
performed whole-exome and transcriptome sequencing of 
biopsies from 150 men with metastatic castrate-resistant 
prostate cancer (mCRPC). They showed that 89% of 
men had clinically actionable genetic mutations, and 8% 
had actionable germline alterations. Based on potential 
sensitivity to PARP inhibitors and the prevalence of BRCA/
ATM mutations they also estimated 19.3% of men could 
benefit from these therapeutic options (46).
Predictive genomic tests
Genomic tests utilising prostate biopsy tissue such as 
OncotypeDx® (a 17-gene assay) can be used in men with 
low-intermediate risk disease on initial prostate biopsy 
considering active surveillance or radical treatment. The 
result is a ‘Genomic Prostate Score’ (GPS) of 1–100. 
Higher values correlate with a higher risk of adverse 
pathology at the time of prostatectomy, risk of 10-year 
prostate cancer-specific mortality and risk of developing 
metastases within 10 years (47). 
The Decipher® test uses prostatectomy tissue to predict 
the risk of 5-year metastases and prostate cancer-specific 
mortality after radical treatment, using an oligonucleotide 
microarray to create a signature ‘genomic classifier’ score 
based on 22 genomic markers, ranging from 0–1. In addition 
to acting independently as a prediction tool, it also improves 
the performance of the CAPRA-S clinicopathological 
risk model. Its use mainly lies in helping determine which 
men with unfavourable radical prostatectomy pathology 
would best benefit from further adjuvant treatments. 
Decipher Biopsy® has also been developed to predict risk 
of metastases, high risk disease and prostate cancer-specific 
mortality from initial biopsies in men with localised disease 
considering active surveillance (48,49). 
The Prolaris® test measures gene expression levels of 31 
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cell cycle genes, in RNA extracted from prostate tumour 
tissue (needle biopsies or prostatectomy specimens). 
It is designed to act as a decision aid in the setting of 
considering active surveillance versus radical treatment in 
men with low/intermediate risk prostate cancer. It estimates 
prostate cancer-specific mortality at 10 years and the risk 
of biochemical recurrence, expressed as a ‘CCP’ (cell-cycle 
progression) score.
ConfirmMDx is an epigenetic DNA methylation 
test performed on prostate biopsy tissue, acting as an 
independent predictor of the likelihood of a positive repeat 
biopsy after initial negative biopsy. SelectMDx, made by the 
same company is used in predicting high versus low-grade 
disease on first prostate biopsy. Unlike previously described 
tests, it uses urine collected after a DRE on which a reverse-
transcriptome PCR assay is performed. This test aims to 
discriminate between men who may avoid a prostate biopsy 
based having on a low risk of high-grade prostate cancer, or 
men who would benefit from a biopsy in whom a high risk 
of harbouring high-grade disease is detected. The 4Kscore® 
goes not require genetic material but acts as a predictive 
blood test, consisting of a panel of four kallikrein markers 
including total PSA, and predicts the risk of Gleason ≥7 
prostate cancer on initial prostate biopsy (50,51).
Prostate cancer consortia investigating genetic 
variants
Led by The Institute of Cancer Research, the UKGPCS 
is recruiting 26,000 men with a diagnosis of prostate 
cancer in order to map the genetic changes associated 
with the disease. This study has provided a wealth of data 
encompassing multiple new prostate cancer susceptibility 
loci (37,38,52). 
Currently, the IMPACT study has enrolled over 3,000 
men (cases and controls) to investigate the outcomes 
of targeted screening in men with BRCA1/2 germline 
mutations and Lynch Syndrome with annual PSA and a 
biopsy threshold of 3.0 ng/mL. Early results have suggested 
targeted screening in this population is beneficial (53). The 
GENPROS study will aim to assess the clinical outcomes of 
1,000 men after prostate cancer treatment with mutations 
in cancer predisposition genes such as BRCA, HOXB13 and 
Lynch Syndrome.
Collaborative, international working has led to the 
creation of multiple consortia interested in pooling large 
numbers of cases with genetic information, allowing large 
scale GWAS. The Prostate Cancer Association Group to 
Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium has brought together over 100 
research groups investigating prostate cancer genetics, also 
forming part of the OncoArray Consortium.
The OncoArray Consortium designed a custom-made 
chip to perform large-scale germline genotyping of over 
400,000 blood samples. This international effort will soon 
publish the most up to date developments in prostate cancer 
susceptibility loci, bringing the total number of known 
pathological SNPs to approximately 170. 
Most GWAS studies establishing risk SNPs, risk-
prediction models using genetic information and genomic 
test validation (i.e., OncotypeDx/Decipher and Prolaris) 
have used genetic information from predominantly 
Caucasian men. Information regarding specific risk alleles 
in men of African ethnicity is therefore grossly lacking, 
hampering the potential for ethnicity-specific genetic risk 
scoring. The Men of African Descent and Carcinoma of 
the Prostate Consortium (MADCaP) is crucially examining 
prostate cancer epidemiology, outcomes and aims to 
catalogue specific genetic mutations in this group of men 
across Africa and North America, with one participating 
centre in London (54). 
The huge scale collection and validation of prostate 
cancer risk alleles as described, will allow an opportunity to 
more precisely define which men will fall into the highest 
risk group. In this vein, scope for further research exists in 
examining the feasibility and survival benefit of offering 
‘early’ radical treatments for men with the highest risk 
profiles.
The PROFILE study
The PROFILE Feasibility study examined the role of 
upfront prostate biopsy regardless of PSA with a PRS in 100 
men. They reported a cancer detection rate of 25%, with 
48% of these being clinically significant cancers requiring 
radical treatment (55). 
Presently, the PROFILE study is recruiting a total of 700 
subjects investigating the role of targeted screening in men 
with a genetic susceptibility to prostate cancer. Germline 
analysis of likely over 100 SNPs will be used in conjunction 
with an outright MRI with prostate biopsy (regardless of 
PSA) in men aged 40–69 with either a FH of prostate cancer 
or black men. The aim is to recruit 350 men in each group, 
with men declining MRI/Biopsy undergoing 6-monthly 
PSA surveillance for a minimum of 5 years. This study will 
determine the association of genetic profiling with MRI/
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prostate biopsy result in men with a genetic susceptibility 
to prostate cancer undergoing targeted, intensive screening. 
Information of prostate cancer incidence, aggressiveness 
and incidence of abnormal MRI and its value in this cohort 
will also be assessed. 
Conclusions
It has been established that a FH of prostate cancer or Afro-
Caribbean ethnicity can predispose men to both earlier 
onset and aggressive disease, with the potential for poor 
outcomes. We know PSA is an imperfect test, and the basis 
for why these groups of men are ‘high risk’ is fundamentally 
genetic in origin. It therefore seems sensible to develop 
targeted screening strategies for these groups of men, using 
a combination of tools to improve cancer detection and 
influence the natural history of their disease. 
Advances in the field of uro-oncology such as the 
diagnostic performance of multi-parametric MRI 
and genomic interrogation have led us to a position 
of potentially use these as screening tools in the right 
populations. In addition, by identifying the value of 
screening high-risk men and potentially extending a 
targeted national screening program to such groups, 
the burden of adverse effects associated with population 
screening could be minimised. 
Acknowledgements
The PROFILE study is funded by Movember/PCUK.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
References
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer 
incidence and mortality worldwide: sources, methods 
and major patterns in GLOBOCAN 2012. Int J Cancer 
2015;136:E359-86.
2. Lloyd T, Hounsome L, Mehay A, et al. Lifetime risk of 
being diagnosed with, or dying from, prostate cancer by 
major ethnic group in England 2008-2010. BMC Med 
2015;13:171.
3. Adolfsson J, Ronstrom L, Lowhagen T, et al. Deferred 
treatment of clinically localized low grade prostate cancer: 
the experience from a prospective series at the Karolinska 
Hospital. J Urol 1994;152:1757-60.
4. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes 
after Monitoring, Surgery, or Radiotherapy for Localized 
Prostate Cancer. N Engl J Med 2016;375:1415-24.
5. Wilt TJ, Brawer MK, Jones KM, et al. Radical 
prostatectomy versus observation for localized prostate 
cancer. N Engl J Med 2012;367:203-13.
6. Liss MA, Chen H, Hemal S, et al. Impact of family history 
on prostate cancer mortality in white men undergoing 
prostate specific antigen based screening. J Urol 
2015;193:75-9.
7. Goldgar DE, Easton DF, Cannon-Albright LA, et al. 
Systematic population-based assessment of cancer risk in 
first-degree relatives of cancer probands. J Natl Cancer 
Inst 1994;86:1600-8.
8. Dong C, Hemminki K. Modification of cancer risks in 
offspring by sibling and parental cancers from 2,112,616 
nuclear families. Int J Cancer 2001;92:144-50.
9. Hemminki K, Czene K. Age specific and attributable risks 
of familial prostate carcinoma from the family-cancer 
database. Cancer 2002;95:1346-53.
10. McWhorter WP, Hernandez AD, Meikle AW, et al. A 
screening study of prostate cancer in high risk families. J 
Urol 1992;148:826-8.
11. Elshafei A, Moussa AS, Hatem A, et al. Does positive 
family history of prostate cancer increase the risk of 
prostate cancer on initial prostate biopsy? Urology 
2013;81:826-30.
12. Angwafo FF. Migration and prostate cancer: an international 
perspective. J Natl Med Assoc 1998;90:S720-3.
13. Ben-Shlomo Y, Evans S, Ibrahim F, et al. The risk 
of prostate cancer amongst black men in the United 
Kingdom: the PROCESS cohort study. Eur Urol 
2008;53:99-105.
14. U.S. Cancer Statistics Working Group. United States 
Cancer Statistics: 1999-2014 Incidence and Mortality 
Web-based Report. Atlanta: U.S. Department of Health 
and Human Services, Centers for Disease Control and 
Prevention and National Cancer Institute; 2017. Available 
online: www.cdc.gov/uscs
15. Papsidero LD, Wang MC, Valenzuela LA, et al. A prostate 
antigen in sera of prostatic cancer patients. Cancer Res 
1980;40:2428-32.
16. Oesterling JE. Prostate specific antigen: a critical 
assessment of the most useful tumor marker for 
adenocarcinoma of the prostate. J Urol 1991;145:907-23.
17. Stamey TA, Caldwell M, McNeal JE, et al. The prostate 
68
Transl Androl Urol 2018;7(1):61-69tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
Eeles and Ni Raghallaigh. A review of genomic-based prostate cancer screening in high risk men
specific antigen era in the United States is over for 
prostate cancer: what happened in the last 20 years? J Urol 
2004;172:1297-301.
18. Moyer VA, Force USPST. Screening for prostate cancer: 
U.S. Preventive Services Task Force recommendation 
statement. Ann Intern Med 2012;157:120-34.
19. UKNSC. Screening for Prostate Cancer Review - 2015 
Update Medicine WIoP; 2015.
20. Hummel S, Chilcott J. Option appraisal: screening for 
prostate cancer model update: Report to the UK National 
Screening Committee March 2013. University of Sheffield, 
Research SoHaR; 2013.
21. Pashayan N, Duffy SW, Neal DE, et al. Implications of 
polygenic risk-stratified screening for prostate cancer on 
overdiagnosis. Genet Med 2015;17:789-95.
22. Pashayan N, Duffy SW, Pharoah P, et al. Mean sojourn 
time, overdiagnosis, and reduction in advanced stage 
prostate cancer due to screening with PSA: implications of 
sojourn time on screening. Br J Cancer 2009;100:1198-204.
23. Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-
based strategy improves prostate-specific antigen-driven 
detection of prostate cancer. Eur Urol 2010;57:79-85.
24. Xu J, Sun J, Kader AK, et al. Estimation of absolute risk 
for prostate cancer using genetic markers and family 
history. Prostate 2009;69:1565-72.
25. Kader AK, Sun J, Reck BH, et al. Potential impact of 
adding genetic markers to clinical parameters in predicting 
prostate biopsy outcomes in men following an initial 
negative biopsy: findings from the REDUCE trial. Eur 
Urol 2012;62:953-61.
26. Karlsson R, Aly M, Clements M, et al. A population-based 
assessment of germline HOXB13 G84E mutation and 
prostate cancer risk. Eur Urol 2014;65:169-76.
27. Laitinen VH, Wahlfors T, Saaristo L, et al. HOXB13 
G84E mutation in Finland: population-based analysis 
of prostate, breast, and colorectal cancer risk. Cancer 
Epidemiol Biomarkers Prev 2013;22:452-60.
28. Ewing CM, Ray AM, Lange EM, et al. Germline 
mutations in HOXB13 and prostate-cancer risk. N Engl J 
Med 2012;366:141-9.
29. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent 
of men with early-onset prostate cancer harbor germline 
mutations in the BRCA2 gene. Am J Hum Genet 
2003;72:1-12.
30. Edwards SM, Evans DG, Hope Q, et al. Prostate cancer 
in BRCA2 germline mutation carriers is associated with 
poorer prognosis. Br J Cancer 2010;103:918-24.
31. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et 
al. Prostate cancer progression and survival in BRCA2 
mutation carriers. J Natl Cancer Inst 2007;99:929-35.
32. Castro E, Goh C, Olmos D, et al. Germline BRCA 
mutations are associated with higher risk of nodal 
involvement, distant metastasis, and poor survival outcomes 
in prostate cancer. J Clin Oncol 2013;31:1748-57.
33. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA 
mutations denote a clinicopathologic subset of prostate 
cancer. Clin Cancer Res 2010;16:2115-21.
34. Cybulski C, Wokolorczyk D, Kluzniak W, et al. An 
inherited NBN mutation is associated with poor prognosis 
prostate cancer. Br J Cancer 2013;108:461-8.
35. Leongamornlert D, Saunders E, Dadaev T, et al. Frequent 
germline deleterious mutations in DNA repair genes in 
familial prostate cancer cases are associated with advanced 
disease. Br J Cancer 2014;110:1663-72.
36. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-
Repair Gene Mutations in Men with Metastatic Prostate 
Cancer. N Engl J Med 2016;375:443-53.
37. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly 
identified loci associated with prostate cancer susceptibility. 
Nat Genet 2008;40:316-21.
38. Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple 
novel prostate cancer predisposition loci confirmed by 
an international study: the PRACTICAL Consortium. 
Cancer Epidemiol Biomarkers Prev 2008;17:2052-61.
39. Macinnis RJ, Antoniou AC, Eeles RA, et al. A risk 
prediction algorithm based on family history and common 
genetic variants: application to prostate cancer with 
potential clinical impact. Genet Epidemiol 2011;35:549-56.
40. Zheng SL, Sun J, Wiklund F, et al. Cumulative association 
of five genetic variants with prostate cancer. N Engl J Med 
2008;358:910-9.
41. Eeles R. Prostate cancer genome-wide association study 
from 89,000 men using the OncoArray chip to identify 
novel prostate cancer susceptibility loci. J Clin Oncol 
2016;34:1525.
42. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 
new prostate cancer susceptibility loci using the iCOGS 
custom genotyping array. Nat Genet 2013;45:385-91, 
91e1-2.
43. Robinson DR, Wu YM, Lonigro RJ, et al. Integrative 
clinical genomics of metastatic cancer. Nature 
2017;548:297-303.
44. Benafif S. The BARCODE 2 Study - The use of 
gentic profiling to guide prostate cancer treatment 
(BARCODE2). Available online: https://clinicaltrials.gov/
ct2/show/NCT02955082
69Translational Andrology and Urology, Vol 7, No 1 February 2018
Transl Androl Urol 2018;7(1):61-69tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
45. Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects 
and Olaparib in Metastatic Prostate Cancer. N Engl J Med 
2015;373:1697-708.
46. Robinson D, Van Allen EM, Wu YM, et al. Integrative 
Clinical Genomics of Advanced Prostate Cancer. Cell 
2015;162:454.
47. Cullen J, Rosner IL, Brand TC, et al. A Biopsy-based 17-
gene Genomic Prostate Score Predicts Recurrence After 
Radical Prostatectomy and Adverse Surgical Pathology 
in a Racially Diverse Population of Men with Clinically 
Low- and Intermediate-risk Prostate Cancer. Eur Urol 
2015;68:123-31.
48. Ross AE, Johnson MH, Yousefi K, et al. Tissue-
based Genomics Augments Post-prostatectomy Risk 
Stratification in a Natural History Cohort of Intermediate- 
and High-Risk Men. Eur Urol 2016;69:157-65.
49. Karnes RJ, Choeurng V, Ross AE, et al. Validation of 
a Genomic Risk Classifier to Predict Prostate Cancer-
specific Mortality in Men with Adverse Pathologic 
Features. Eur Urol 2018;73:168-75.
50. Punnen S, Pavan N, Parekh DJ. Finding the Wolf in 
Sheep's Clothing: The 4Kscore Is a Novel Blood Test 
That Can Accurately Identify the Risk of Aggressive 
Prostate Cancer. Rev Urol 2015;17:3-13.
51. Cucchiara V, Cooperberg MR, Dall’Era M, et al. Genomic 
Markers in Prostate Cancer Decision Making. Eur Urol 
2017. [Epub ahead of print].
52. Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification 
of seven new prostate cancer susceptibility loci through a 
genome-wide association study. Nat Genet 2009;41:1116-21.
53. Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted 
prostate cancer screening in men with mutations in 
BRCA1 and BRCA2 detects aggressive prostate cancer: 
preliminary analysis of the results of the IMPACT study. 
BJU Int 2011;107:28-39.
54. Consortium launches genotyping effort. Cancer Discov 
2013;3:1321-2.
55. Castro E, Mikropoulos C, Bancroft EK, et al. The 
PROFILE Feasibility Study: Targeted Screening of Men 
With a Family History of Prostate Cancer. Oncologist 
2016;21:716-22.
Cite this article as: Eeles R, Ni Raghallaigh H. Men with a 
susceptibility to prostate cancer and the role of genetic based 
screening. Transl Androl Urol 2018;7(1):61-69. doi: 10.21037/
tau.2017.12.30
